{"filings":[{"id":2420717,"accession_number":"0001023024-26-000071","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-08-24T11:01:19+00:00","items":["5.02","9.01"],"status":"ready","headline":"ANI Pharmaceuticals appoints Henry Gosebruch to board; director Shanmugam resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Henry Gosebruch appointed to ANI board effective Aug 19, 2026; term expires at 2027 annual meeting.","Gosebruch is CEO of Lakefront Biotherapeutics (formerly Galapagos) since May 2025; ex-CEO of Neumora, ex-EVP Chief Strategy Officer at AbbVie.","Gosebruch receives initial restricted stock award with grant date fair value $525,000, vesting in 3 equal annual installments.","Samy Shanmugam resigned as director effective Aug 23, 2026; remains Head of R&D and COO of New Jersey Operations.","Gosebruch brings 30+ years experience; expected to strengthen business development and capital allocation as ANI accelerates Rare Disease transformation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2115045,"accession_number":"0001023024-26-000068","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-08-07T11:00:11+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharma Q2 revenue $266M (+25.9%), GAAP EPS $1.05, adjusted EPS $2.21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $266.0M, +25.9% YoY; GAAP net income $24.7M ($1.05/diluted) vs $8.1M prior year.","Cortrophin Gel revenue $117.1M, +43.5% YoY; ILUVIEN down 16.1% to $18.7M on shipment timing.","Adjusted non-GAAP EBITDA $71.6M (+32.4%); adjusted diluted EPS $2.21 vs $1.80 prior.","FY26 total revenue guidance reaffirmed $1,080-1,140M; Cortrophin Gel guidance narrowed to $520-540M from $540-575M.","Board authorized $100M share repurchase program through May 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":503506000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582076,"accession_number":"0001023024-26-000056","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-05-21T20:13:01+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ANI Pharma stockholders approve Amended 2022 Stock Plan, elect seven directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved Amended 2022 Stock Plan; authorized share reserve increased by 962,000 to 8,222,000 shares.","All seven director nominees elected: Haughey, Lalwani, Leonard, Pera, Shanmugam, Tannenbaum, Thoma.","Ratified Ernst & Young as independent auditor for fiscal year 2026.","Advisory say-on-pay vote approved; future votes to be held every one year.","Amended plan includes no-hedging policy on repricing and director compensation cap of $750k per year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50601,"accession_number":"0001023024-26-000054","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-05-13T12:27:46+00:00","items":["7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals posts updated investor presentation for May 2026; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company published updated investor presentation on IR website on May 13, 2026.","Presentation intended for use in meetings with investors and analysts.","Filing does not include financial results or material operational changes.","Exhibit text was not provided in the filing, preventing summary of specific content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90665,"accession_number":"0001023024-26-000049","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma Q1 rev $237.5M (+20.5%); raises FY 2026 guidance, authorizes $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $237.5M (+20.5% YoY); GAAP diluted EPS $1.28; adj non-GAAP diluted EPS $2.05.","Cortrophin Gel rev $75.1M (+42.1%); ILUVIEN rev $19.3M (+19.5%); Generics rev $105.4M (+6.8%).","Raised FY 2026 guidance: rev $1,080M-$1,140M; adj EBITDA $285M-$300M; adj diluted EPS $9.19-$9.69.","Board authorized $100M share repurchase program through May 2029; cash from operations $58.4M in Q1.","Harmony Agreement contributed $15M upfront + $6.5M royalties; $10M milestone expected in Q2/Q3 2026."],"consensus_eps_estimate":1.3308,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":237462000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90664,"accession_number":"0001023024-26-000034","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals dismisses EisnerAmper, appoints Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EisnerAmper dismissed as independent auditor effective April 1, 2026; Audit Committee approved.","EisnerAmper reports for FY 2025 and 2024 had no adverse opinion or qualification.","No disagreements or reportable events during fiscal years 2025, 2024, and through dismissal.","Ernst & Young (EY) appointed as new independent auditor for fiscal year 2026, effective April 1, 2026.","No prior consultations with EY regarding accounting matters under Regulation S-K Item 304."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100379,"accession_number":"0001023024-26-000017","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals issues investor presentation; no specific updates in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation provided at Raymond James 47th Annual Institutional Investors Conference on March 3, 2026.","Presentation dated March 2026; no financial or operational updates disclosed in the filing.","Content of the presentation is not included in the exhibit text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100378,"accession_number":"0001023024-26-000013","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma reports record Q4 revenue $247M, EPS $1.18; reaffirms 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total net revenue $247.1M (+29.6% YoY); Rare Disease segment $131.3M (+50.8%), Cortrophin Gel $111.4M (+87.6%).","Q4 GAAP diluted EPS $1.18; adjusted diluted EPS $2.33. Full year revenue $883.4M (+43.8%).","Generics Q4 revenue $100.8M (+28.2%) driven by partnered launch and new products.","Reaffirms FY2026 guidance: total revenue $1.055-1.115B; Cortrophin Gel $540-575M; adjusted EBITDA $275-290M.","Cash and equivalents $285.6M; operating cash flow $185.2M in 2025."],"consensus_eps_estimate":2.0353,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":883366000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100377,"accession_number":"0001023024-26-000005","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharma 2025 rev ~$854-873M, Cortrophin Gel up 76% YoY; 2026 rev target $1.06-1.12B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 total net revenues expected within or above $854M-$873M guidance ( ~39% YoY growth).","Cortrophin Gel net rev $347.8M in 2025 (+76% YoY); Q4 Cortrophin Gel $111.4M (+88% YoY).","2026 guidance: total net rev $1,055M-$1,115M, Cortrophin Gel $540M-$575M, adj EBITDA $275M-$290M, adj EPS $8.83-$9.34.","Plans to expand Rare Disease sales force by ~90 in mid-2026 to target acute gouty arthritis flares.","Unrestricted cash $285M at Dec 31, 2025; ILUVIEN+YUTIQ combined rev $74.9M in 2025."],"consensus_eps_estimate":2.0353,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":883366000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116706,"accession_number":"0001023024-25-000113","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals names Thomas J. Haughey as new Chairman; Patrick Walsh to retire at 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick D. Walsh will not seek re-election as director and steps down as Chairman; no disagreement with board or management.","Thomas J. Haughey elected Chairman; he has served on the board since May 2018.","Jeanne A. Thoma replaces Haughey as Chair of Audit and Finance Committee; Haughey remains on the committee.","Walsh's retirement effective after the 2026 Annual Meeting of Stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116705,"accession_number":"0001023024-25-000110","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals posts updated investor presentation; no new financials disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Published updated investor presentation on November 10, 2025, available on website.","Filing contains no specific financial results, guidance changes, or operational metrics.","Presentation intended for use in meetings with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116704,"accession_number":"0001023024-25-000107","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharmaceuticals reports record Q3 2025 revenue and raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly net revenues of $227.8 million, up 53.6% year-over-year.","Purified Cortrophin Gel net revenues rose 93.8% to $101.9 million.","Adjusted non-GAAP EBITDA of $59.6 million, up 69.8%.","Raised 2025 total net revenue guidance to $854M-$873M and adjusted EPS to $7.37-$7.64.","GAAP diluted EPS of $1.13 vs. net loss of $1.27 per share in prior year period."],"consensus_eps_estimate":1.7888,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":636306000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133156,"accession_number":"0001023024-25-000099","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.02","3.03"],"status":"ready","headline":"ANI converts all Series A preferred to common; 602,900 shares issued, preferred eliminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Sep 26, 2025, ANI mandatorily converted 20,000 preferred shares into 482,320 common shares at $41.4662/share.","On Aug 14, 2025, Ampersand converted 5,000 preferred shares into 120,580 common shares at the same price.","All 25,000 preferred shares converted into 602,900 common shares; no preferred shares remain outstanding.","Mandatory conversion triggered because 20-day VWAP exceeded 170% of conversion price ($70.50) after second anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133155,"accession_number":"0001023024-25-000089","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals files 8-K for investor presentation at conferences; no financial details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Nikhil Lalwani to present at H.C. Wainwright and Morgan Stanley healthcare conferences on Sep 8-9, 2025.","Updated investor presentation furnished as Exhibit 99.1 but content not available in extracted filing.","No specific financial results, guidance, or material operational updates disclosed in the filing body.","Filing under Items 2.02 and 7.01 is routine and does not contain new performance data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133154,"accession_number":"0001023024-25-000081","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma Q2 record revenues $211.4M, EPS $0.36; lifts FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $211.4M (+53.1% YoY); GAAP EPS $0.36 vs ($0.14); record adjusted EBITDA $54.1M (+62.8%).","Rare Disease rev $104.0M (Cortrophin Gel $81.6M, +66%; ILUVIEN/YUTIQ $22.3M).","Generics rev $90.3M (+22.1%); driven by new launches including first-to-market prucalopride.","Raised FY2025 guidance: rev $818M–$843M; adj EBITDA $213M–$223M; adj EPS $6.98–$7.35.","Cash & equivalents $217.8M; year-to-date CFO $110.8M."],"consensus_eps_estimate":1.4484,"consensus_eps_actual":1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":408493000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133153,"accession_number":"0001104659-25-071769","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ANI Pharmaceuticals loses jury verdict in royalty dispute with CG Oncology; no damages awarded","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury returned verdict on July 29, 2025 awarding no damages to ANI on its unjust enrichment counterclaim against CG Oncology.","Court previously granted CG Oncology's partial summary judgment on Brulotte defense, finding royalty provision unenforceable.","ANI intends to challenge the verdict through post-trial motions and/or an appeal.","Case stems from a 2010 Agreement for a 5% royalty on worldwide net sales of cretostimogene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133152,"accession_number":"0001023024-25-000074","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ANI Pharma announces NEW DAY clinical trial results; no specifics in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Item 8.01 with press release and conference call on NEW DAY Study results.","Presentation attached as Exhibit 99.1; data not reproduced in the 8-K text.","No revenue, EPS, or numeric endpoints provided in the filing body.","Investors should review the full presentation for study outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133151,"accession_number":"0001023024-25-000072","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"ANI Pharma posts preliminary Q2 ILUVIEN/YUTIQ revenue of $22.3M; NEW DAY trial misses primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary combined ILUVIEN/YUTIQ net revenues for Q2 2025: $22.3M.","NEW DAY trial primary endpoint: mean supplemental injections 2.4 (ILUVIEN) vs. 2.5 (aflibercept); p=0.756, not significant.","Secondary endpoint met: mean time to first supplemental injection 185.4 vs. 132.8 days (p<0.001).","Post-hoc per-protocol analysis: ILUVIEN arm 1.8 vs. 2.5 supplemental injections (p=0.029); total 2.8 vs. 7.5 injections.","Safety: 41% treatment-related TEAE in ILUVIEN arm (cataract, IOP increase) vs. 3% in aflibercept arm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149759,"accession_number":"0001023024-25-000058","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals presents at Jefferies conference; no material new information disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["President & CEO Nikhil Lalwani presented at Jefferies Global Healthcare Conference on June 4, 2025.","Investor presentation attached as Exhibit 99.1 but no specific financial updates or guidance are provided in the filing.","Filing does not contain earnings results, M&A, or other material operational changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149758,"accession_number":"0001023024-25-000056","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"ANI shareholders approve doubling authorized common shares to 66M and equity plan amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Certificate of Amendment raising authorized common shares from 33,333,334 to 66,000,000; effective May 22, 2025.","Amended 2022 Stock Incentive Plan approved (15,056,885 for, 1,202,893 against, 10,460 abstain).","Amended 2016 Employee Stock Purchase Plan approved (16,173,976 for, 89,098 against, 7,164 abstain).","Eight director nominees elected; EisnerAmper LLP ratified as auditor; say-on-pay advisory approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149757,"accession_number":"0001023024-25-000049","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals presents at conference; no new material financial disclosure","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Nikhil Lalwani presenting at H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025.","Investor presentation furnished as Exhibit 99.1; no specific financial results or guidance included in the 8-K.","Presentation likely covers corporate overview and recent developments, but details not provided in filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149756,"accession_number":"0001023024-25-000044","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma posts record Q1 revenue $197.1M (+43%); raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 net revenue $197.1M (+43.4% YoY); Rare Disease $69.0M (Cortrophin Gel $52.9M, +43.1%).","Record adjusted non-GAAP EBITDA $50.7M (+34.9%); adjusted diluted EPS $1.70, up from $1.21 YoY.","Generics revenue $98.7M (+40.5%) driven by new launches including first-to-market prucalopride.","Raised 2025 guidance: net revenue $768M-$793M, EBITDA $195M-$205M, adjusted EPS $6.27-$6.62."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":197122000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149755,"accession_number":"0001104659-25-045937","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ANI Pharmaceuticals supplements proxy statement on stock plan share reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of March 24, 2025, total stock options outstanding: 571,880 (weighted avg exercise price $46.28, remaining term 3.68 yrs).","Performance/restricted stock awards: 1,866,153 shares; shares available for future grant: 1,177,800.","Inducement grants (non-shareholder approved) comprise 184,989 options at avg exercise price $29.63, term 5.57 yrs.","Company seeks approval of Amended and Restated 2022 Stock Incentive Plan; no changes to other proposals or meeting date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168786,"accession_number":"0001023024-25-000024","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals buys out perpetual royalty on ILUVIEN/YUTIQ for $17.25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $17.25M one-time cash to SWK to eliminate 3.125% perpetual royalty on worldwide net revenues of ILUVIEN and YUTIQ.","No further royalty due from January 1, 2025 forward; buyout covers all future net revenues.","Funded with cash on hand; enhances financial flexibility for Retina portfolio growth.","CEO Nikhil Lalwani states the transaction reflects commitment to maximizing long-term value of ILUVIEN and YUTIQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168785,"accession_number":"0001023024-25-000021","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals receives FDA approval to expand ILUVIEN label for chronic non-infectious uveitis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ILUVIEN for chronic non-infectious uveitis affecting posterior segment (NIU-PS), expanding beyond DME.","ANI plans to market ILUVIEN under the combined label in the U.S. later this year.","Extended supply agreement with Siegfried through 2029; equipment upgrade and capacity expansion planned.","ILUVIEN is already approved for both DME and NIU-PS in 17 European countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168784,"accession_number":"0001023024-25-000018","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals presents at Leerink Partners Global Healthcare Conference on March 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Nikhil Lalwani presents at Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025.","Investor presentation attached as Exhibit 99.1 to the Form 8-K filed on March 11, 2025.","The information is furnished under Items 2.02 and 7.01 and is not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168783,"accession_number":"0001023024-25-000012","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma Q4 net rev $190.6M (+44.8%), adj EPS $1.63; raises 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q4 net rev $190.6M (+44.8% YoY); organic growth (ex-Alimera) +23.8%.","Rare Disease rev $87.0M: Cortrophin Gel $59.4M (+42.3%), ILUVIEN/YUTIQ $27.6M.","Adj. non-GAAP EBITDA $50.0M (+65.7%); diluted GAAP loss per share $0.55.","Adj. non-GAAP diluted EPS $1.63 vs $1.00 in prior year quarter.","2025 guidance raised: rev $756-776M, adj. EBITDA $190-200M, adj. EPS $6.12-6.49."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":614376000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168782,"accession_number":"0001023024-25-000006","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals presents at Guggenheim Biotech Conference; no material news disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 for Guggenheim Biotech Conference on Feb 5, 2025, but content not provided in this excerpt.","No specific financial results, guidance, or material events are disclosed in the Form 8-K filing.","The filing only notes the presentation; substantive information is missing from the exhibit appended to this analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168781,"accession_number":"0001023024-25-000002","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharma prelim Q4/FY24 Cortrophin Gel rev $197.8-198.4M; FY25 rev guidance $739-759M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cortrophin Gel net rev Q4: $59.2-59.8M; FY24: $197.8-198.4M.","ILUVIEN/YUTIQ net rev Q4: $26.6-27.2M; post-acquisition period (Sep 16-Dec 31): $30.4-31.0M.","FY24 total rev, adjusted EBITDA, adjusted EPS expected at or above guidance issued Nov 8, 2024.","FY25 outlook: total rev $739-759M (24-27% growth vs FY24 midpoint); adj EBITDA $182-192M.","Full FY24 and detailed FY25 guidance to be reported in late Feb 2025 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":614376000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185910,"accession_number":"0001023024-24-000106","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals presents at Jefferies London; no material updates in limited exhibit text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["President & CEO Nikhil Lalwani presented at the 2024 Jefferies London Healthcare Conference on 11/20/2024.","The filing includes an investor presentation (Exhibit 99.1), but the provided exhibit text is incomplete or missing.","No specific financial guidance, material events, or operational updates are discernible from the filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185909,"accession_number":"0001023024-24-000100","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharmaceuticals posts record Q3 revenue of $148.3M, raises 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly net revenue of $148.3M (+12.5% YoY); Cortrophin Gel revenue $52.6M (+76.8%).","GAAP net loss of $24.2M (-$1.27 diluted EPS) vs net income of $9.5M year ago; adjusted non-GAAP EPS of $1.34.","Completed Alimera acquisition on Sept 16, adding ILUVIEN and YUTIQ; contributed $3.9M revenue in partial quarter.","Raised FY2024 guidance: net rev $594-602M, adjusted EBITDA $149-153M, adjusted EPS $4.90-$5.05.","New capital structure with $316.25M 2.25% convertible notes due 2029; expected to reduce interest expense ~$39M annually."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":423802000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202483,"accession_number":"0001023024-24-000093","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"ANI Pharma closes Alimera Sciences acquisition; $5.50/sh cash plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Sept 16, 2024; Alimera shareholders received $5.50 cash per share plus one CVR per share.","CVRs tied to net revenue of ILUVIEN and YUTIQ: $140M by FY2026, $160M by FY2027; max payout $0.25 per CVR per milestone.","Financed with $325M senior secured term loan from JPMorgan-led syndicate plus available cash.","Pro forma results show combined net loss of $3.4M for H1 2024 and $51.6M for FY2023.","Audited Alimera financials and unaudited pro forma combined statements filed as Exhibits 99.1-99.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202482,"accession_number":"0001023024-24-000088","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ANI Pharma completes Alimera acquisition; expects high single-digit to low double-digit EPS accretion in 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Alimera for $5.50/share plus CVR up to $0.50/share based on 2026-27 net revenue targets; repaid $72.5M Alimera debt.","Alimera adds ~$105M in pro forma 2024 revenue; Rare Disease segment to become ~45% of pro forma revenues.","New capital: $316.25M 2.25% convertible notes due 2029; new $325M term loan; interest expense reduced ~$39M annually.","Expects high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS; substantially accretive thereafter; $35-38M adj. EBITDA.","Cortrophin Gel record new patient starts in Aug; ophthalmology team >3,600 physicians; 14 generic products launched YTD; maintains standalone 2024 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202481,"accession_number":"0000950103-24-012144","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"ANI closes $316.25M convertible notes offering; upsizes due to demand","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$316.25M aggregate principal of 2.25% convertible senior notes due 2029 issued; upsized from $250M initial offering.","Net proceeds of ~$306.8M; $40.6M used for capped call transactions to reduce potential dilution.","Remainder plus cash on hand used to repay ~$292.5M outstanding under existing senior secured credit agreement.","Entered new $400M credit facility ($325M delayed draw term loan + $75M revolver) to partially finance pending Alimera Sciences merger.","Capped call transactions cap price $114.02/share, a 100% premium over $57.01 closing price on pricing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202480,"accession_number":"0000950103-24-011897","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals prices upsized $275M 2.25% convertible notes due 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $275M (upsized from $250M); net proceeds ~$266.8M (or ~$306.8M if full option exercised).","Notes bear 2.25% interest semi-annually, mature Sept 1, 2029; initial conversion price ~$74.11/share, 30% premium.","Proceeds: ~$35.3M for capped call transactions; remainder to repay existing senior secured term loan facility.","Company plans new $325M delayed draw term loan and $75M revolving facility concurrently with closing.","Initial purchasers have 13-day option to purchase additional $41.25M principal amount of notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202479,"accession_number":"0000950103-24-011822","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ANI Pharma proposes $250M convertible notes due 2029; to repay term loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering $250M in Convertible Senior Notes due Sept 1, 2029; underwriters option for additional $37.5M.","Proceeds used to repay existing senior secured term loan; new $325M delayed draw term loan and $75M revolver planned.","Capped call transactions expected to reduce dilution on conversion of notes.","Interest rate, conversion rate, and other terms to be set at pricing.","Notes unsecured; redemption at ANI's option after Sept 1, 2027 under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202478,"accession_number":"0001023024-24-000083","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma Q2 record revenues $138M (+18% YoY); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net revenues $138.0M (+18.4% YoY); Rare Disease Cortrophin Gel $49.2M (+102.4% YoY).","GAAP net loss $(2.7)M ($(0.14)/share); adjusted non-GAAP diluted EPS $1.02; adjusted EBITDA $33.2M.","Raised FY 2024 guidance: rev $540M-$560M, adj. EBITDA $140M-$150M, adj. EPS $4.38-$4.82.","On track to acquire Alimera Sciences (~$5.50/sh cash + CVR) in Q3 2024, adding ILUVIEN and YUTIQ."],"consensus_eps_estimate":null,"consensus_eps_actual":0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":275470000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218612,"accession_number":"0001023024-24-000070","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"ANI Pharma to acquire Alimera Sciences for $5.50/share + CVR, funded by $280M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal consideration: $5.50 cash plus one CVR per Alimera share; adds ~$105M in branded revenue to ANI's rare disease segment.","CVR pays up to $0.25 per milestone: $0.25 if 2026 net revenue > $140M, $0.25 if 2027 net revenue > $160M.","Financing: $280M committed debt from JPMorgan and Blackstone; deal expected to close by Dec 21, 2024.","Accretion: high single to low double digit adj. non-GAAP EPS accretion in 2025; $35-38M adj. EBITDA incl. $10M cost synergies.","Caligan Partners (~32.1% holder) agreed to vote in favor; termination fee $10.4M under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218611,"accession_number":"0001023024-24-000067","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals to present at Jefferies conference; limited filing information available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Nikhil Lalwani will present at the 2024 Jefferies Global Healthcare Conference on June 5, 2024.","Investor presentation attached as Exhibit 99.1; full content not available from filing excerpt.","No earnings, guidance, or transactional data could be extracted from the provided materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218610,"accession_number":"0001023024-24-000063","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ANI Pharmaceuticals shareholders approve Amended 2022 Stock Plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At May 21 annual meeting, all eight director nominees elected; Thomas Haughey received 14.8M for, 2.1M against.","Shareholders ratified EisnerAmper as auditor for FY2024: 18.0M for, 56.7K against.","Advisory say-on-pay approved: 16.1M for, 762.7K against, 1.2M broker non-votes.","Amended 2022 Stock Incentive Plan approved: 16.0M for, 871.2K against, 1.2M broker non-votes.","Plan increases equity pool; forms for director (1-yr cliff) and employee (4-yr graded) restricted stock filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218609,"accession_number":"0001023024-24-000059","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals CEO presents at investor conference; no financial results disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["President & CEO Nikhil Lalwani participated in Capital One Securities Biotech/Biopharma Disruptors Event on May 14, 2024.","Investor presentation attached as Exhibit 99.1 was referenced but not included in the provided text.","No new financial or operational data, guidance changes, or material events can be extracted from the filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218608,"accession_number":"0001023024-24-000055","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharmaceuticals Q1 2024: record revenue $137.4M, EPS $0.82; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $137.4M (+28.7% YoY); GAAP diluted EPS $0.82 vs $0.06; adjusted non-GAAP EPS $1.21.","Rare Disease segment (Cortrophin Gel) revenue $36.9M, up 126.2% YoY on higher volume.","Generics, Established Brands and Other segment revenue $100.5M, up 11.1% YoY; launched six new generics.","FY2024 guidance reaffirmed: revenue $520M-$542M; adjusted EBITDA $135M-$145M; adjusted EPS $4.26-$4.67.","Ended quarter with $228.6M cash; sold Oakville facility for $14.2M, recognized $9.7M gain on CG Oncology IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":137430000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218607,"accession_number":"0001023024-24-000050","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals provides investor presentation at Piper Sandler symposium; details unavailable","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing announces CEO Nikhil Lalwani and CFO Stephen Carey meeting investors at Piper Sandler Spring Biopharma Symposium on April 17, 2024.","Exhibit 99.1 investor presentation furnished but not included in provided text; no financial data or guidance disclosed in filing body.","Presentation not filed under Securities Act; standard Form 8-K items 2.02 and 7.01 invoked."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238502,"accession_number":"0001023024-24-000034","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals furnishes investor presentation; no new financial disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated investor presentation as Exhibit 99.1 dated March 2024.","Presentation provided at Leerink Partners Global Biopharma Conference on March 12, 2024.","No specific financial results or material events disclosed in the filing body.","Exhibit content not available; summary cannot be produced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238501,"accession_number":"0001023024-24-000024","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharmaceuticals Q4 revenue up 39.7% YoY; issues 2024 guidance with Cortrophin Gel growth 52-61%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenues $131.7M (+39.7% YoY); GAAP diluted EPS $0.04; adjusted non-GAAP diluted EPS $1.00.","Rare Disease (Cortrophin Gel) Q4 revenue $41.7M (+137.3% YoY) with record new patient starts and prescribers.","Full-year 2023 net revenue $486.8M, adjusted EBITDA $133.8M, operating cash flow $119.0M.","2024 guidance: net revenue $520-542M, Cortrophin Gel $170-180M, adjusted EBITDA $135-145M, adjusted EPS $4.26-$4.67.","Generics segment revenue $71.8M (+23.8% YoY); 11 new products launched in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":486816000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238500,"accession_number":"0001023024-24-000015","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals sells former Oakville, ON manufacturing facility for C$19.2M (US$14.2M)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price C$19.2M (~US$14.2M); buyer paid 5% deposit (~US$710k) with second 5% after due diligence.","Buyer has 5 business day due diligence period; closing expected by end of March 2024.","Sale includes land, building (~101,111 sq ft), chattels and fixtures; sold 'as is' with customary conditions.","ANI retains deposits if buyer defaults; deposits returned if ANI defaults or due diligence fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238499,"accession_number":"0001023024-24-000007","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals to present at Guggenheim Healthcare Talks Biotechnology Conference","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["CEO Nikhil Lalwani and senior leadership to present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Feb 8, 2024.","Investor presentation dated February 2024 attached as Exhibit 99.1.","Disclosure made under Items 2.02 and 7.01 of Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238498,"accession_number":"0001023024-24-000002","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals updates investor deck at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated January 2024 used in meetings with investors on Jan 8, 2024.","No specific financial results, guidance, or material events disclosed in the filing body.","Exhibit 99.1 contains the updated investor presentation; content not summarized here.","Filing is a routine update under Items 2.02 and 7.01 with no new operational details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256013,"accession_number":"0001023024-23-000045","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ANI Pharmaceuticals to Present at Jefferies 2023 London Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["President & CEO Nikhil Lalwani will present at the Jefferies 2023 London Healthcare Conference in London, UK on November 15, 2023.","An investor presentation dated November 2023 is furnished as Exhibit 99.1 and incorporated by reference into Items 2.02 and 7.01.","The information in the Form 8-K is furnished and not deemed filed for purposes of Section 18 of the Exchange Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256012,"accession_number":"0001023024-23-000041","cik":1023024,"company_name":"ANI PHARMACEUTICALS INC","ticker":"ANIP","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ANI Pharma Q3 revenue $131.8M (+57% YoY); raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 net revenue $131.8M, up 57.3% YoY; GAAP net income $9.5M ($0.45 diluted EPS).","Adjusted non-GAAP EBITDA $36.5M (+98% YoY); adj. diluted EPS $1.27 vs $0.58 YoY.","Cortrophin Gel net sales $29.7M (+136% YoY); full-year Cortrophin guidance raised to $100M-$107M.","FY2023 revenue guidance raised to $468M-$478M (prev. $425M-$445M); adj. EPS guided $4.29-$4.57.","Generics/Established Brands revenue $102.1M (+43.4% YoY); 5 new products launched in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":355162000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1857396045.8175144,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-08T23:59:59+00:00|256012"}